早期乳腺癌治疗决策中整合胚系基因检测的差距
基于两个SEER登记处(佐治亚州和洛杉矶)2014至2015年诊断的3672例乳腺癌患者调查(应答率68%),666例报告接受基因检测。约半数患者未与遗传咨询师讨论结果,平均风险携带意义未明变异(VUS)者中51%接受双侧乳房切除术,部分外科医生对BRCA1/2 VUS与致病突变采取相同管理。
要点
- 666例报告基因检测,三分之二在外科治疗前检测,无私人保险者更常经历延迟。
- BRCA1/2或其他基因致病突变者双侧乳房切除术率最高(较高风险80%,平均风险85%)。
- VUS患者双侧乳房切除术也常见(较高风险43%,平均风险51%),提示对结果理解有限。
核心结论
- 许多乳腺癌患者接受基因检测但从未见过遗传咨询师;半数平均风险VUS患者接受双侧乳房切除术,提示部分外科医生对结果理解有限,需应对基因检测个性化沟通的挑战。
研究设计与样本
- 基于人群的样本,纳入2014至2015年诊断、由两个SEER登记处(佐治亚州和洛杉矶)识别的乳腺癌患者,调查基因检测经历(N=3,672,应答率68%),并与SEER数据合并。
- 根据基因检测指南定义检测前致病突变携带风险较高的患者亚组,并调查患者的主治外科医生关于基因检测和结果管理的情况。
- 分析遗传咨询和检测的模式及相关因素,以及检测结果对双侧乳房切除术使用的影响。
主要发现
- 666例患者报告接受基因检测;三分之二患者在手术治疗前检测,但无私人保险者更常经历延迟。
- 约半数患者(较高风险57%,平均风险42%)与遗传咨询师讨论结果。
- BRCA1/2或其他基因致病突变者双侧乳房切除术率最高(较高风险80%,平均风险85%)。
- VUS患者双侧乳房切除术也常见(较高风险43%,平均风险51%)。
- 外科医生讨论检测的自信随乳腺癌患者数量增加而增加,但许多外科医生(高 volume 24%,低 volume 50%)对BRCA1/2 VUS患者与BRCA1/2致病突变患者管理相同。
关键数值与推荐
- 较高检测前风险患者中57%与遗传咨询师讨论结果,平均风险患者中42%。
- 致病突变患者双侧乳房切除术率:较高风险80%,平均风险85%。
- VUS患者双侧乳房切除术率:较高风险43%,平均风险51%。
- 外科医生对BRCA1/2 VUS与致病突变管理相同:高 volume 24%,低 volume 50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Genetic testing for breast cancer risk is evolving rapidly, with growing use of multiple-gene panels that can yield uncertain results. However, little is known about the context of such testing or its impact on treatment. Methods A population-based sample of patients with breast cancer diagnosed in 2014 to 2015 and identified by two SEER registries (Georgia and Los Angeles) were surveyed about genetic testing experiences (N = 3,672; response rate, 68%). Responses were merged with SEER data. A patient subgroup at higher pretest risk of pathogenic mutation carriage was defined according to genetic testing guidelines. Patients' attending surgeons were surveyed about genetic testing and results management. We examined patterns and correlates of genetic counseling and testing and the impact of results on bilateral mastectomy (BLM) use. Results Six hundred sixty-six patients reported genetic testing. Although two thirds of patients were tested before surgical treatment, patients without private insurance more often experienced delays. Approximately half of patients (57% at higher pretest risk, 42% at average risk) discussed results with a genetic counselor. Patients with pathogenic mutations in BRCA1/2 or another gene had the highest rates of BLM (higher risk, 80%; average risk, 85%); however, BLM was also common among patients with genetic variants of uncertain significance (VUS; higher risk, 43%; average risk, 51%). Surgeons' confidence in discussing testing increased with volume of patients with breast cancer, but many surgeons (higher volume, 24%; lower volume, 50%) managed patients with BRCA1/2 VUS the same as patients with BRCA1/2 pathogenic mutations. Conclusion Many patients with breast cancer are tested without ever seeing a genetic counselor. Half of average-risk patients with VUS undergo BLM, suggesting a limited understanding of results that some surgeons share. These findings emphasize the need to address challenges in personalized communication about genetic testing.
引用
- Kurian AW, Li Y, Hamilton AS, et al. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. J Clin Oncol. 2017. PMID: 28402748. doi:10.1200/JCO.2016.71.6480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。